The Food and Drug Administration (FDA) approved a treatment for advanced pancreatic cancer on Wednesday, August 26, 2026. The treatment, a once-daily pill named daraxonrasib, is manufactured by Revolution Medicines and will be marketed under the brand name Rasonque. It has been approved for patients who have previously undergone other treatments for this aggressive form of cancer.
✓ AI-Debiased Article
4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
FDA Approves New Treatment for Advanced Pancreatic Cancer
The FDA has approved daraxonrasib, a new once-daily pill for advanced pancreatic cancer, providing a new treatment option for patients who have not responded to previous therapies. The drug is produced by Revolution Medicines and will be sold under the brand name Rasonque.
Companies
Revolution Medicines
Compare the coverage
Annotating as
No note attached
on this article.
Read next
Original vs. Neutral
Original Headline
FDA approves groundbreaking new pancreatic cancer drug
Neutral Headline
FDA Approves New Treatment for Advanced Pancreatic Cancer